Lux Research sees an increasingly self-sufficient and self-sustaining biopharma market in China. Business models and value chains are evolving away from low cost manufacturing for export into servicing the China market itself. Evidence of increasing velocity of expansion and acquisition deals are detailed in this report along with increasing innovation and development of local formulation and delivery technology companies within China, some of whom rival their western counterparts in terms of technology sophistication and market reach. This report details comparison of such companies along with notable deals and trends.
Table of Contents
Table of Contents
Executive Summary
Landscape
Status of the Global Formulation and Delivery field
The Current Formulation and Delivery Landscape
Landscape Conclusions
Analysis
Government Led Investments in China Formulation and Delivery companies
About the NSTMP
The Emerging China Formulation and Delivery Ecosystem
Investments channeling into China F/D
Global activities congregate in China
China-based Formulation and delivery companies leverage local resources and market knowledge to compete
Comparison of select companies from various regions focusing in Drug Delivery Devices
Comparison of select companies from various regions focusing on Formulation-based Delivery Technologies
Outlook
Methodology
Lux Methodology for Analyzing and Comparing Companies
Drug-delivery Companies' Performance Is Measurable
Company Position Depends on Performance in Three Dimensions
About Lux Research
The Expanding Formulation and Delivery Market in China published by Lux Research in January 2, 2012. This report consists of Pages: 25 and the price starts from US $ 3500.
The contents of this page may be different from the latest version. Please contact us for details.
